skip to main content

Rogel Cancer Center News

Two U-M Rogel Cancer Center Research Projects Compete in STAT Madness

A team led by Costas Lyssiotis, Ph.D. in the Rogel Cancer Center and Department of Molecular & Integrative Physiology, made the bracket for a study that shows why pancreatic cancer cells stubbornly resist treatment with a common chemotherapy drug. It could pave the way to better treatment options.

A joint Engineering/Rogel Cancer Center team led by Eusik Yoon, Ph.D. with former Rogel director Max Wicha, M.D., is in the competition for their work to develop a way to separate cancer cells out of blood samples taken from patients, so they can be tested for genetic signatures that could guide treatment.

Can one of them make it all the way, and defend the tournament title that Michigan scientists won last year? It all depends on how many members of the public vote for these true-blue entries!

Study finds immunotherapy, targeted therapy combination may be option for advanced kidney cancer

The multi-site phase Ib/II study looked at the combination of the immunotherapy drug pembrolizumab with bevacizumab for metastatic renal cell carcinoma. Pembrolizumab is known commercially as Keytruda and bevacizumab is known as Avastin.

Anti-Leukemia Compound, MI-3454, Begins Testing in a Clinical Trial

MI-3454 resulted in complete remission in mouse models. Now, a Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.

The compound, dubbed MI-3454, inhibits the protein-protein interaction between menin and Mixed Lineage Leukemia 1 (MLL1) protein. It induced complete remission in mice transplanted with patient-derived cells containing MLL1 genes with translocations.

Cervical Cancer is Preventable But Remains a Tragic Problem Worldwide

Globally, especially in low- and middle-income countries in Africa, Latin America, the Caribbean and Asia, an estimated 569,847 women were diagnosed with cervical cancer in 2018, with 85% of that burden occurring in low- and middle-income countries.
coronavirus

Coronavirus and Michigan Medicine

Michigan Medicine is following the evolving situation closely and actively preparing for potential patients. We have activated our comprehensive emergency response teams, which are ready at all times for emergencies. We are monitoring patients and visitors to quickly identify those with travel-related risk factors or potential contact with infected people. We also are preparing for the possibility of community spread within the state of Michigan by providing standard face masks to patients with coughs or other symptoms when they enter our healthcare facilities. We are discouraging visitors who are sick from visiting the hospital, as we always do during flu season.
Illuminate masthead

Introducing our annual publication, Illuminate

Illuminate is created as a way to highlight the research taking place -- from basic science to clinical care and population sciences -- at the Rogel Cancer Center. The overarching goal of Illuminate is to foster collaboration as we highlight some of our most significant advances, as well as place our findings in the larger context of the cancer research and patient care landscape.

 

University of Michigan pathologist, Dr. Cody Carter, explains in this video how pathologists and other laboratory professionals help to diagnose patients' biopsies. This behind-the-scenes look into the University of Michigan Department of Pathology shows how tissue is prepared to be viewed under a microscope and what pathologists are looking for in order to determine a diagnosis.